No formal hypothesis tests were performed on the secondary outcomes and summaries of the posterior distributions were provided for descriptive purposes only.ĭAnalyzed as time-to-event outcomes.
A maximum of 1980 participants were included within the secondary analyses.īAn OR or HR greater than 1 equates to the threshold for superiority to control for the primary outcome.ĬAn OR or HR less than 1.2 equates to the threshold for futility for the primary outcome.
CrI indicates credible interval ECMO, extracorporeal membrane oxygenation HR, hazard ratio ICU, intensive care unit OR, odds ratio WHO, World Health Organization.ĪData for the secondary analyses excluded participants who had been randomized within another domain within the moderate stratum and then randomized to the immunoglobulin domain in the severe stratum (excluded 7 participants). From the primary analysis using a bayesian cumulative logistic model, the median-adjusted odds ratio was 0.97 (95% credible interval, 0.83-1.15) for the convalescent plasma group compared with the no convalescent plasma group, yielding a probability of superiority of 37.8% over the no convalescent plasma group and a probability of futility of 99.4%.Īdditional data are available in Supplement 2 (eTables 5-6). B, The color red represents worse values and blue represents better values, the deepest red is death and deepest blue is 21 days. The difference in the height of the 2 curves at any point represents the difference in the cumulative probability of having a value for days without organ support of less than or equal to that point on the x-axis. The curves that rise more slowly are more favorable.
#Matrix 6.0 huong dan pdf trial#
GThe primary analysis of alternative interventions within the immunoglobulin domain is estimated from a model that adjusts for patient factors and for assignment to other interventions.Ī, The ordinal scale includes death (in-hospital death, the worst possible outcome) and a score of 0 to 21 (the numbers of days alive without organ support) by trial group as the cumulative proportion (y-axis) for each trial group by day (x-axis), with death listed first. 16ĬRequired to have high-flow nasal cannula oxygenation, invasive or noninvasive mechanical ventilation, or vasopressor or inotropic infusion.ĭRandomization started with balanced assignment and then adapted with preferential assignment to those interventions that appeared most favorable until predefined statistical triggers of superiority or futility were met.ĮAdditional information about delayed convalescent plasma appears in Supplement 2 (eTables 1 and 5 and eFigure 1).įThe results for patients who were not critically ill were partially pooled with critically ill patients in the primary analysis, which provides a more precise estimate of the treatment effect of convalescent plasma. A domain refers to a common therapeutic area (eg, antiviral therapy) within which several interventions or intervention dosing strategies could be randomly assigned. ASee Supplement 1 for additional information about the platform trial.īPatients could have met more than 1 ineligibility criterion.
0 kommentar(er)
